investigated the synergetic antitumor impact of transfusion DC-CIK combined with MWA in Stage I/II HCC patients and reported a significantly longer disease-free survival with increased serum CD3+ (P = 0.049) and CD8/CD28+ (P = 0.045) levels compared to those seen after MWA alone (83). This evidence concerns the gene CD8A and hepatocellular carcinoma.